Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Jun;35(6):359-64.
doi: 10.1002/clc.21994. Epub 2012 Apr 20.

Effect of telmisartan on paroxysmal atrial fibrillation recurrence in hypertensive patients with normal or increased left atrial size

Roberto Fogari  1 , Annalisa Zoppi, Pamela Maffioli, Amedeo Mugellini, Paola Preti, Tiziano Perrone, Giuseppe Derosa
Affiliations
Randomized Controlled Trial

Effect of telmisartan on paroxysmal atrial fibrillation recurrence in hypertensive patients with normal or increased left atrial size

Roberto Fogari et al. Clin Cardiol. 2012 Jun.

Abstract

Background: Hypertension is the most prevalent and potentially modifiable risk factor for atrial fibrillation (AF). In a previous secondary prevention study, the authors observed that the angiotensin II receptor blocker telmisartan was more effective than the calcium channel blocker amlodipine in preventing AF relapse in hypertensive patients with normal atrial size.

Hypothesis: Telmisartan may be more effective than amlodipine in preventing AF recurrence in hypertensive patients with paroxysmal AF and normal or increased left atrial dimension (LAD).

Methods: The authors assigned 378 mild hypertensive outpatients in sinus rhythm, but with ≥2 episodes of AF in the previous 6 months, to 1 of 2 groups. Group 1 comprised patients with LAD <40 mm in females and <45 mm in males. Group 2 comprised patients with LAD >40 mm and <45 mm in females and >45 mm and <50 mm in males. In both groups, patients were randomly treated with telmisartan or amlodipine for 1 year.

Results: Systolic and diastolic blood pressure were similarly reduced by telmisartan and amlodipine in both groups. The AF recurrence rate was significantly lower in the telmisartan-treated patients than in the amlodipine-treated patients in both group 1 (12 vs 39, P < 0.01) and group 2 (40 vs 59, P < 0.05). Under telmisartan, the AF recurrence rate was significantly lower in group 1 than in group 2 (12.9% vs 42.1%, P < 0.05). Time to a first AF relapse was significantly longer with telmisartan than with amlodipine in both group 1 (176 ± 94 days vs 74 ± 61 days, P < 0.05) and group 2 (119 ± 65 days vs 38 ± 35 days, P < 0.05).

Conclusions: Telmisartan was more effective than amlodipine in preventing AF recurrences in hypertensive patients with paroxysmal AF.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study design. Abbreviations: BP, blood pressure.
Figure 2
Figure 2
Flow diagram of the study. Abbreviations: AE, adverse event; BP, blood pressure.
Figure 3
Figure 3
Rate of atrial fibrillation recurrence stratified by presence or absence of LA dilation. Abbreviation: LA, left atrial.
See this image and copyright information in PMC

References

    1. Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population‐based estimates. Am J Cardiol. 1998;82:2N–9N. - PubMed
    1. European Heart Rhythm Association , European Association for Cardio‐Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369–2429. - PubMed
    1. Fang MC, Go AS, Chang Y, et al; ATRIA Study Group. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2008;51:810–815. - PMC - PubMed
    1. Verdecchia P, Reboldi G, Gattobigio R, et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension. 2003;41:218–223. - PubMed
    1. Okin PM, Gerdts E, Wachtell K, et al. Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial fibrillation. J Hypertens. 2010;28:1534–1540. - PubMed

Publication types

MeSH terms